Dermatomyositis
Definition
Dermatomyositis is a rare, acquired inflammatory myopathy with an autoimmune background, characterized by involvement of the skeletal muscle system and the skin. It is a systemic connective tissue disease that falls within the spectrum of idiopathic inflammatory myopathies and combines symmetrical proximal muscle weakness with characteristic skin rashes.
The pathogenesis is based on a disturbance in innate and adaptive immune responses, leading to complement activation and damage to the capillaries in the muscles and skin. This microvascular damage results in ischemia, intramuscular edema, degeneration of muscle fibers, and distinctive cutaneous findings. Skin lesions include the heliotrope rash (violaceous discoloration around the eyes), Gottron’s papules (erythematous scaly lesions over the dorsal joints), and the “V sign” on the chest.
The disease manifests at two peak age ranges: the juvenile form (ages 5–15) and the adult form (ages 40–60), more frequently affecting women. In adults, up to 30% of cases may be associated with malignancies, necessitating thorough oncological screening with every new diagnosis.
Specialized care, experience, and long-term scientific training
• Comprehensive and Effective Treatments
• Maximum Efficacy
• No Side Effects
Symptoms
Dermatomyositis presents with characteristic skin and muscle-related symptoms.
Skin Symptoms:
• Erythema and swelling of the face, especially around the eyes (heliotrope rash)
• Gottron’s papules: erythematous or violaceous plaques with scaling over the dorsal aspects of joints (metacarpophalangeal, phalangeal)
• Photosensitivity and rashes in sun-exposed areas (the “V sign” on the chest and “shawl sign” on the neck/shoulders)
• Periungual changes: telangiectasias and epidermal thickening around the nails
• Itching and scaly lesions, especially on the scalp
Musculoskeletal and Systemic Symptoms:
• Symmetrical proximal muscle weakness in the shoulders and pelvic girdle
• Difficulty walking, climbing stairs, rising from a seated position
• Reduced ability to lift objects or comb hair
• Dysphagia and dysphonia due to pharyngeal and laryngeal muscle involvement
• Respiratory difficulty due to diaphragm or accessory respiratory muscle involvement
• Arthralgias or mild arthritis
• Fever and general malaise during active disease phases
• Cardiac involvement (rare): myocarditis or heart failure
Causes
Dermatomyositis is an autoimmune inflammatory disease in which the immune system malfunctions and begins attacking healthy tissues, particularly skeletal muscles and small blood vessels in the skin. This inflammatory process causes muscle weakness, pain, and characteristic skin lesions.
The exact cause remains unknown, but the development of the disease appears to result from a complex interaction of genetic and environmental factors. Certain viruses and bacteria may trigger dysfunctional immune activation through molecular mimicry mechanisms. Additionally, environmental triggers such as ultraviolet radiation, toxins, chronic stress, or specific medications (e.g., statins) may contribute to disease onset.
In adults over age 50, dermatomyositis may represent a paraneoplastic syndrome and precede or accompany the onset of malignancy, most commonly in the lungs, ovaries, pancreas, breast, or gastrointestinal tract.
Genetically, the presence of specific HLA antigens (e.g., HLA-B8, DR3, and DQA1*0501) has been associated with increased risk of the disease. Furthermore, individuals with a family history of other autoimmune diseases – such as systemic lupus erythematosus, rheumatoid arthritis, or type 1 diabetes – appear to be at greater risk for developing dermatomyositis.
Potential Complications
Dermatomyositis increases the risk of swallowing difficulty (dysphagia), especially when the esophageal muscles are affected, potentially leading to weight loss and malnutrition. Aspiration pneumonia and respiratory problems may also occur due to thoracic muscle weakness causing dyspnea.
The disease is also linked to other conditions, including Raynaud’s phenomenon, autoimmune connective tissue diseases (e.g., lupus, rheumatoid arthritis, scleroderma, Sjögren’s syndrome), cardiovascular disease, and lung diseases. Additionally, in adults it is associated with a higher risk of developing cancer, especially in the cervix, lungs, pancreas, breast, ovaries, and gastrointestinal tract.
Diagnosis
Following clinical evaluation of symptoms, the dermatologist usually recommends comprehensive laboratory testing (CPK, LDH, aldolase), specific antibody panels (MSA, ANA), and imaging studies (chest X-ray, MRI, ECG) to confirm dermatomyositis. Muscle biopsy is considered crucial for diagnosis. At the same time, screening for underlying malignancy is essential.
In addition to blood tests assessing muscle enzymes and autoantibody presence, diagnostic evaluation may include electrocardiography, electromyography, MRI, skin and muscle biopsy, and cancer screening.
Treatment
Dermatomyositis is primarily treated with corticosteroids (prednisolone), which are highly effective, with approximately 75% of patients showing improvement. Treatment begins with high doses, which are gradually tapered once remission is observed.
If the disease does not respond to corticosteroids, cytotoxic agents such as methotrexate, azathioprine, and cyclophosphamide may be used. These agents support treatment but require careful monitoring for potential side effects.
In addition to pharmacologic therapy, physical therapy and regular exercise are crucial for maintaining mobility and reducing muscle weakness. In some cases, particularly when calcinosis is present, bisphosphonates may reduce subcutaneous calcium deposits.
Furthermore, care from a specialized multidisciplinary team in centers experienced in managing this disease is recommended, especially when complications like severe respiratory distress are present, as these can lead to serious disability or worsen the patient’s overall health.